Abbott India Limited Earnings Summary — Q1 FY2027
Abbott India Reports 17.1% Profit Growth in Q1 FY2027 Amid Leadership Transition
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue grew 6.1% sequentially in Q1 FY2027.
- Revenue of ₹1,814 Cr is 4.3% higher year-on-year.
- Revenue has compounded at 10.8% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit has reached its highest level in 10 quarters.
- Net profit of ₹429 Cr is 17.1% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 19.5% annualised across the period.
- Operating margin stands at 28.8% in Q1 FY2027.
- Operating margin expanded by 318 bps year-on-year.
- Over the last two years operating margin has expanded by 371 bps.
- PBT margin is 31.6%.
- Expense growth of -0.1% remained below revenue growth of 4.3%.
- Operating profit of ₹523 Cr is 17.3% higher year-on-year.
- Operating leverage continues to improve.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 79/100 (Strong) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Stable | 1,814 | 1,710 | 1,724 | 1,757 | 1,738 | 1,605 | 1,614 | 1,633 | 1,558 | 1,439 |
| Expenses | Stable | 1,291 | 1,229 | 1,261 | 1,255 | 1,293 | 1,176 | 1,178 | 1,194 | 1,167 | 1,109 |
| Operating Profit | Improving | 523 | 481 | 463 | 502 | 446 | 429 | 436 | 439 | 391 | 330 |
| Operating Margin | Stable | 28.8% | 28.1% | 26.9% | 28.6% | 25.6% | 26.7% | 27.0% | 26.9% | 25.1% | 22.9% |
| Other Income | Stable | 75 | 76 | 70 | 70 | 73 | 76 | 72 | 60 | 67 | 81 |
| Interest | Improving | 6 | 6 | 5 | 8 | 6 | 4 | 2 | 3 | 3 | 3 |
| Depreciation | Stable | 20 | 19 | 19 | 19 | 19 | 18 | 18 | 18 | 18 | 18 |
| Profit Before Tax | Improving | 572 | 531 | 509 | 546 | 493 | 483 | 488 | 479 | 437 | 390 |
| Tax | Improving | 144 | 136 | 133 | 131 | 127 | 116 | 127 | 121 | 109 | 103 |
| Net Profit | Improving | 429 | 395 | 376 | 415 | 366 | 367 | 361 | 359 | 328 | 287 |
| Net Margin | Stable | 23.6% | 23.1% | 21.8% | 23.6% | 21.1% | 22.9% | 22.4% | 22.0% | 21.1% | 19.9% |
Key Takeaways
- Profit after tax for Q1 FY2027 rose 17.1% year-on-year to ₹428.52 Crores, significantly outperforming revenue growth.
- Revenue from operations grew a modest 4.3% YoY to ₹1,813.68 Crores, while showing a stronger 6.1% sequential improvement.
- Operational efficiency improved as total expenses were flat year-on-year at ₹1,316.84 Crores, despite higher employee benefit costs.
- Leadership transition confirmed: Mr. Sudarshan Jain appointed as Chairman effective August 13, 2026, succeeding Mr. Munir Shaikh.
- The pharmaceutical segment remains the sole business driver, with a strategy focused on expanding 'extra-urban' geography presence.
- Tax expenses increased to ₹143.69 Crores in the quarter, reflecting higher taxable income bases.
Management Guidance
Management targets becoming a $1 billion revenue organization by 2025/2026 by growing faster than the Indian Pharma Market through portfolio lifecycle management and expansion into Tier II/III towns.
Sentiment Shift
Improving
Margins continue to expand as the company shifts from volume-based share to value-based therapy shaping, with strong bottom-line outperformance compared to revenue growth.
Outlook
The company plans to launch 75 new products over the next five years, focusing on 'Loss of Exclusivity' opportunities and specialized therapy areas like Menopause (Femoston) and Thyroid awareness.
From the Annual Report (Key Quotes)
“We are the only multinational among the top 10 companies in the Indian pharmaceutical market growing faster than the market.”
“We move from therapy shaping to diagnosis, to the pill... we go beyond the pill, we focus on adherence, we focus on patient care.”
“Our entire growth last couple of years has come from productivity increase. It hasn't come from adding people.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Abbott India Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.